The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
about
Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experienceThe initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnershipRepeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trialEfficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferTolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, LiberiaThe effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataComparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa.Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan childrenEvaluation of antimalarial resistance marker polymorphism in returned migrant workers in ChinaFixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies.Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Health providers' perceptions of clinical trials: lessons from Ghana, Kenya and Burkina Faso.Population pharmacokinetics of artesunate and amodiaquine in African childrenMaximizing antimalarial efficacy and the importance of dosing strategies.The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial.High adherence to malaria treatment: promising results of an adherence study in South Kivu, Democratic Republic of the CongoClinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa.The global pipeline of new medicines for the control and elimination of malariaHaemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa.Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysisImpact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trialSafety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire.Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009In vitro studies on the sensitivity pattern of Plasmodium falciparum to anti-malarial drugs and local herbal extractsNovel anti-malarial combinations and their toxicity.A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice.Antimalarial Preclinical Drug Development: A Single Oral Dose of A 5-Carbon-linked Trioxane Dimer Plus Mefloquine Cures Malaria-Infected Mice.Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa.Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.Standardised versus actual white cell counts in estimating thick film parasitaemia in African children under five.Why do policies change? Institutions, interests, ideas and networks in three cases of policy reform.Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose.Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial.Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria.
P2860
Q21034090-17366473-097D-45FF-99B4-5C99AE6CD5F6Q21034118-AB266A82-39D3-4130-AA9D-C2FF725DBAC5Q24597403-6F46B73A-8D12-4F65-AA40-85367AD12959Q28691396-65148EF9-AD33-4CCA-AF01-8E70B6F5178BQ28691509-BF03C47B-8A5B-453F-8782-517A146D6834Q30936416-B5AABC8D-685B-4285-8485-F555E7873D36Q33399342-47497E23-B161-46BA-9DDE-03084918B155Q33876535-3377A495-EB4F-4F22-8B56-A456A05446D2Q34478487-5393479A-1197-45DE-AAD5-13A16598F002Q34600201-FB531112-6992-4083-A6AD-77DFF67B1AD1Q34922481-5D612F5E-08DA-41CD-ACBC-A6BAF44FB259Q34996451-C8390374-463D-486C-A710-282B5D5EBB22Q35004430-D1008CE1-6F65-4E1A-B293-81A429489F9DQ35245962-BC40D716-0C8C-4B85-A090-05A06C7A4E8FQ35560610-B0DDA8A7-856B-4BC0-8B49-B50063C98A9DQ35575394-657D35B9-9F9A-4461-B13D-1AA622D0BF36Q35588265-78B02129-738C-401A-8F4E-88CEC7FE9EBDQ36138872-8ADE43C0-F836-4064-BC56-AB67EDD14F15Q36146216-8C3EE3C1-CAD8-4485-A233-742335955740Q36190074-D0BFC99F-B617-4CE6-A17B-EE832AB725FEQ36309115-32C6F618-5205-45EE-AFC8-1CD8CAE5C1B1Q36320249-C4CD3918-E9B1-4D04-BE62-8CFABDD0A659Q36413462-6B2D3250-1B27-4A0B-9087-A0CEE0DD5799Q36617963-4157396F-7B27-4B79-945D-D4FD6AB3C147Q37350167-1AC27999-3BF5-4C4A-AB79-8FFE9F8F4E6CQ37361298-81A40608-FB7B-4947-BC8A-60C33FC6EE19Q37555147-3046288A-4C14-42DA-A0F1-5215CD812CF5Q37703517-EF8A4F71-428C-4D38-900D-726F500C68DCQ37717358-287F28D5-AAC9-460D-89D7-8F65684EA370Q38203334-9FBFF465-4DB5-4A4C-AB9C-52C077DC21BAQ38480612-4C366CCD-49A4-470F-83E2-162AA5499B89Q38497186-AF6C01D6-E8E8-4347-94EB-1F0B2CF5B009Q38870446-2769CF82-3890-48AD-82E8-8653B55EAEE7Q38928995-2DF890A2-DFF5-4D98-862C-4EF81591A664Q39322791-B8510F05-AF36-4485-AEED-024FEE498424Q39454076-1A771F25-7FDB-426A-A3E7-60D1985D3B32Q40369518-CAD81919-1146-45B0-960B-147AA790F60FQ42021778-6BF95195-6CCB-40D8-B87C-28E89321F280Q43927844-EC852A5A-DC27-40EC-9A55-CF579278DC61Q47995732-34469C03-96E1-41F8-A20D-08B8FB98D235
P2860
The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The efficacy and safety of a n ...... plicated Plasmodium falciparum
@en
The efficacy and safety of a n ...... licated Plasmodium falciparum.
@nl
type
label
The efficacy and safety of a n ...... plicated Plasmodium falciparum
@en
The efficacy and safety of a n ...... licated Plasmodium falciparum.
@nl
prefLabel
The efficacy and safety of a n ...... plicated Plasmodium falciparum
@en
The efficacy and safety of a n ...... licated Plasmodium falciparum.
@nl
P2093
P2860
P921
P356
P1433
P1476
The efficacy and safety of a n ...... plicated Plasmodium falciparum
@en
P2093
Adama Gansané
Alfred B Tiono
Amadou T Konaté
Amidou Diarra
Amidou Ouédraogo
Caroline C Morgan
Jean René Kiechel
Piero L Olliaro
Walter R J Taylor
P2860
P2888
P356
10.1186/1475-2875-8-48
P577
2009-03-16T00:00:00Z
P5875
P6179
1020746145